

Randomised ambulatory management of primary pneumothorax (RAMPP)

Submission date 05/08/2015	Recruitment status No longer recruiting	☒ Prospectively registered ☒ Protocol
Registration date 06/08/2015	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 12/09/2023	Condition category Respiratory	☐ Individual participant data

Plain English summary of protocol

Background and study aims

Pneumothorax - air in the pleural space, or more widely known as a collapsed lung - is common (~3,000 patients per year in the UK). The term primary spontaneous pneumothorax (PSP) is used to describe those cases that occur in the absence of trauma, in patients with no underlying established lung disease. Not all patients need to have treatment; such patients are just closely observed until the condition improves on its own. However, many patients will need treatment to re-inflate the lung. In some cases aspiration (removal) of air from the pleural space using cannula and syringe will be enough, but many will need to have a chest drain inserted with standard underwater seal. The average hospital in-patient stay for people having this treatment is 6-8 days. Portable 'ambulatory' devices (such as the Rocket Pleural Vent) provide the option to treat these patients as an outpatient while their lung reinflates. This study compares ambulatory to standard (in-patient treatment with aspiration/chest drain) management of primary pneumothorax.

Who can participate?

Participants aged between 16 and 55 with a PSP.

What does the study involve?

Participants are randomly allocated into one of two groups. Those in group 1 undergo ambulatory management of their PSP. Those in group 2 undergo standard (in-patient treatment with aspiration/chest drain) management of their PSP. Primary outcome is total hospital stay up for up to 30 days. The study also investigates whether digitally measured air leak can predict short term outcome (prolonged air leak and requirement for surgery) and whether radiological evidence (on CT scanning) of emphysema-like change and inflammation (swelling of the lung) can predict long term outcome (recurrence rates at 12 months). Patients are assessed at the start of the study with blood tests taken and are reviewed daily either on the ward (standard management group) or as an outpatient (ambulatory group) with chest x-ray, air leak measurement and assessment of breathlessness and chest discomfort. Patients who do not require treatment, will be invited to participate in the observational part of the study and after their initial assessment will be discharged but return for follow up. All patients are followed-up at 1 week post treatment completion (including a CT scan at 2 weeks post completion of treatment), and then at 1, 6 & 12 months after the start of the study.

What are the possible benefits and risks of participating?

One potential benefit of taking part in the study is that those randomly assigned to portable device have the opportunity to be discharged with the device in place. Any procedure on the chest carries some risk. Most patients having a chest drain do not have any problems. However, occasionally patients may experience pain, bleeding or infection at the site of the drain. This risk is the same whether they are in the trial or not. If a patient is enrolled after already having had a chest drain, they may require an extra procedure if they are randomised to the ambulatory device. Patients have at least 6 chest x-rays during their participation in this study, although 4 of these would need to be done whether they were in the study or not. They will also have a CT scan (for research). There are theoretical health risks from excessive radiation exposure, but chest x-rays are the safest tests (the radiation dose is only equivalent to around four days' worth of normal background radiation) and the CT scan will be the lowest possible dose (equivalent of one year's worth of normal background radiation).

Where is the study run from?

University of Oxford, Churchill Hospital (UK)

When is the study starting and how long is it expected to run for?

July 2015 to December 2018

Who is funding the study?

Medical Research Council and the National Institute for Health Research (UK)

Who is the main contact?

Miss Magda Laskawiec-Szkonter

Contact information

Type(s)

Scientific

Contact name

Miss Magda Laskawiec-Szkonter

Contact details

University of Oxford

Churchill Hospital

Old Road

Oxford

United Kingdom

OX3 7LE

Additional identifiers

Protocol serial number

19214

Study information

Scientific Title

Ambulatory management of primary pneumothorax: a randomised controlled trial

Acronym

RAMPP

Study objectives

This study compares ambulatory to standard (in-patient treatment with aspiration/chest drain) management of primary pneumothorax.

Ethics approval required

Old ethics approval format

Ethics approval(s)

NRES Committee South Central - Oxford A, 19/05/2015, ref: 15/SC/0240

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Pneumothorax

Interventions

1. Ambulatory Device, Rocket Pleural vent insertion
2. Standard Treatment, Aspiration +/- chest drain

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Not provided at time of registration

Primary outcome(s)

To assess whether use of an ambulatory device (Rocket Pleural Vent) and treatment strategy reduces hospital stay. Total length of stay in hospital up to 30 days post randomisation. Up to 30 days post randomisation.

Key secondary outcome(s)

1. Determine whether digitally measured air leak and its evolution over treatment, can predict short term clinical trajectory in patients with pneumothorax, including requirement for prolonged drainage and need for thoracic surgical intervention
 - 1.1. Digitally measured air leak (using Thopaz device), from day 0 (immediately post

intervention) to day 4 (or until the chest drain/device removal)

1.2. Rate of surgical referral/failure of medical therapy, on day 4

1.3. Number of pleural procedures required during primary admission, from primary admission until completion of treatment

1.4. Rate of lung re-expansion by comparing the percentage of the hemithorax occupied by the pneumothorax using a CXR scoring system, daily until completion of treatment

2. Establish whether radiological evidence (on CT scanning) of emphysema-like changes (ELC) and inflammation, and serum markers of inflammation can predict long term outcome.

Measured at 1 week post completion of treatment and 1, 6 and 12 months post enrolment assessed at follow-up clinic.

2.1. CT evidence of ELC and inflammation: number and size of bullae at apices, and bronchial wall thickness in lung apices (surrogate for inflammation), measured at 1 week post completion of treatment and 1, 6 and 12 months post enrolment assessed at follow-up clinic.

2.2. Correlation with recurrence rate (and time to recurrence) assessed at follow-up clinic

2.3. Serum highly sensitive C-reactive protein (CRP) level on blood test. Measured at baseline.

3. Assess whether ambulatory care and early discharge is safe and cost-effective in the treatment of PSP.

3.1. Rate of complications: intervention site bleeding or infection, blockage of device and need for additional procedure. Measured from initial admission until 1 week post completion of treatment.

3.2. NHS-related healthcare costs by including use of equipment and devices, consumables, medications, and staff and theatre, initial and subsequent hospitalisations over the 12 month follow-up, and outpatient contacts.

3.3. Incremental cost per QALY gained when ambulatory care is compared to standard care, measured from initial admission throughout follow-up.

4. Determine whether patient experience is improved with an ambulatory device (Rocket Pleural Vent): pain of procedure, breathlessness, quality of life assessments (EQ-5D-5L), and time to return to working status.

4.1. Patient related factors: procedural pain/discomfort and breathlessness on VAS scoring system, analgesia usage, and generic health-related and disease-specific quality of life as measured using the Euroqol 5 dimensions 5 levels (EQ-5D-5L). Measured from initial admission throughout follow-up.

4.2. Time to return to work and total days off work, measured from initial admission throughout follow-up.

5. Assess recurrence rate of pneumothorax. Radiological evidence (CXR and or CT) of recurrence. Measured at 1 week post completion of treatment and at 1, 6 and 12 months post enrolment assessed at follow-up clinic.

Completion date

31/03/2020

Eligibility

Key inclusion criteria

1. Presenting with primary spontaneous pneumothorax as confirmed by a chest radiograph or a CT scan

2. Age ≥ 16 years old and ≤ 55 years old

3. Ability to consent to participation

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

236

Key exclusion criteria

1. Known or suspected underlying lung disease (including >20 pack year smoking history)
2. Evidence of tension pneumothorax (these patients should be treated immediately as medical emergencies).
3. Females who are pregnant or lactating
4. Inability to consent or comply with the trial requirements
5. Contraindication to thoracic procedure. (Only applies to patients being enrolled into Intervention or Control arms – i.e. not observational cohort)
6. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial

Date of first enrolment

27/08/2015

Date of final enrolment

31/03/2019

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

University of Oxford

Churchill Hospital

Old Road

Oxford

United Kingdom

OX3 7LE

Sponsor information

Organisation

CTRG (University of Oxford)

ROR

<https://ror.org/052gg0110>

Funder(s)**Funder type**

Government

Funder Name

Medical Research Council

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Funder Name

National Institute for Health Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	04/07/2020	06/07/2020	Yes	No
Protocol article		11/04/2019	12/09/2023	Yes	No
HRA research summary			28/06/2023	No	No
Other publications	Cost-effectiveness	17/08/2022	12/09/2023	Yes	No